


10/510678

10/510678

10/510678



**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
ORGANISATION MONDIALE DE LA PROPRIÉTÉ INTELLECTUELLE**

34, chemin des Colombettes, Case postale 18, CH-1211 Genève 20 (Suisse)  
Téléphone: (41 22) 338 91 11 - e-mail: wipo.mail @ wipo.int. - Fac-similé: (41 22) 733 54 28

**PATENT COOPERATION TREATY (PCT)  
TRAITÉ DE COOPÉRATION EN MATIÈRE DE BREVETS (PCT)**

**CERTIFIED COPY OF THE INTERNATIONAL APPLICATION AS FILED  
AND OF ANY CORRECTIONS THERETO**

**COPIE CERTIFIÉE CONFORME DE LA DEMANDE INTERNATIONALE, TELLE QU'ELLE  
A ÉTÉ DÉPOSÉE, AINSI QUE DE TOUTES CORRECTIONS Y RELATIVES**

International Application No. }  
Demande internationale n° }

**PCT/IB02/01258**

International Filing Date }  
Date du dépôt international }

**09 April 2002  
(09.04.02)**

Geneva/Genève,  
**28 April 2003  
(28.04.03)**


**International Bureau of the  
World Intellectual Property Organization (WIPO)**

**Bureau International de l'Organisation Mondiale  
de la Propriété Intellectuelle (OMPI)**

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

**BEST AVAILABLE COPY**



**J.-L. Baron**

Head, PCT Receiving Office Section  
Chef de la section "office récepteur du PCT"

## PCT REQUEST

Original (for SUBMISSION) - printed on 08.04.2002 12:59:38 PM

|         |   |  |
|---------|---|--|
| 0       | For receiving Office use only   |  |
| 0-1     | International Application No.   | PCT / IB 0 2 / 0 1 2 5 8   |
| 0-2     | International Filing Date   | 0 9 APRIL 2002 (0 9. 04. 02)   |
| 0-3     | Name of receiving Office and "PCT International Application"  | INTERNATIONAL BUREAU OF WIPO<br>PCT International Application                      |
| 0-4     | Form - PCT/RO/101 PCT Request   |  |
| 0-4-1   | Prepared using  | PCT-EASY Version 2.92<br>(updated 01.01.2002)                                      |
| 0-5     | Petition<br>The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty |  |
| 0-6     | Receiving Office (specified by the applicant)   | International Bureau of the World<br>Intellectual Property Organization<br>(RO/IB) |
| 0-7     | Applicant's or agent's file reference   | 06052PC  |
| I       | Title of invention  | ENHANCER SEQUENCE OF THE<br>5-AMINOLEVULINIC SYNTHASE GENE                         |
| II      | Applicant   |  |
| II-1    | This person is:   | applicant only   |
| II-2    | Applicant for   | all designated States except US  |
| II-4    | Name  | UNIVERSITÄT BASEL  |
| II-5    | Address:  | Petersgraben 35<br>CH-4003 Basel<br>Switzerland                                    |
| II-6    | State of nationality  | CH   |
| II-7    | State of residence  | CH   |
| III-1   | Applicant and/or inventor   |  |
| III-1-1 | This person is:   | applicant and inventor   |
| III-1-2 | Applicant for   | US only  |
| III-1-4 | Name (LAST, First)  | MEYER, Urs, Albert   |
| III-1-5 | Address:  | Wartenbergstrasse 31<br>CH-4104 Oberwil<br>Switzerland                             |
| III-1-6 | State of nationality  | CH   |
| III-1-7 | State of residence  | CH   |

## PCT REQUEST

Original (for SUBMISSION) - printed on 08.04.2002 12:59:38 PM

|         |                                  |   |
|---------|----------------------------------|---|
| III-2   | <b>Applicant and/or inventor</b> |   |
| III-2-1 | This person is:                  | applicant and inventor                                |
| III-2-2 | Applicant for                    | US only   |
| III-2-4 | Name (LAST, First)               | FRASER, David, John                                   |
| III-2-5 | Address:                         | Hagentalerstrasse 7<br>CH-4055 Basel<br>Switzerland   |
| III-2-6 | State of nationality             | US  |
| III-2-7 | State of residence               | CH  |
| III-3   | <b>Applicant and/or inventor</b> |   |
| III-3-1 | This person is:                  | applicant and inventor                                |
| III-3-2 | Applicant for                    | US only   |
| III-3-4 | Name (LAST, First)               | KAUFMANN, Michel, R.                                  |
| III-3-5 | Address:                         | Nonnenweg 56<br>CH-4055 Basel<br>Switzerland          |
| III-3-6 | State of nationality             | CH  |
| III-3-7 | State of residence               | CH  |
| III-4   | <b>Applicant and/or inventor</b> |   |
| III-4-1 | This person is:                  | applicant and inventor                                |
| III-4-2 | Applicant for                    | US only   |
| III-4-4 | Name (LAST, First)               | PODVINEC, Michael                                     |
| III-4-5 | Address:                         | Davidsbodenstrasse 28<br>CH-4056 Basel<br>Switzerland |
| III-4-6 | State of nationality             | CH  |
| III-4-7 | State of residence               | CH  |
| III-5   | <b>Applicant and/or inventor</b> |   |
| III-5-1 | This person is:                  | applicant and inventor                                |
| III-5-2 | Applicant for                    | US only   |
| III-5-4 | Name (LAST, First)               | ZUMSTEG, Adrian                                       |
| III-5-5 | Address:                         | Rufacherstrasse 84<br>CH-4055 Basel<br>Switzerland    |
| III-5-6 | State of nationality             | CH  |
| III-5-7 | State of residence               | CH  |

## PCT REQUEST

Original (for SUBMISSION) - printed on 08.04.2002 12:59:38 PM

|        |  |   |
|--------|--|---|
| IV-1   | <b>Agent or common representative; or address for correspondence</b><br>The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: | agent   |
| IV-1-1 | Name   | E. BLUM & CO.   |
| IV-1-2 | Address:   | Vorderberg 11<br>CH-8044 Zürich<br>Switzerland  |
| IV-1-3 | Telephone No.  | ++41 1 261 54 54  |
| IV-1-4 | Facsimile No.  | ++41 1 251 67 17  |
| IV-1-5 | e-mail   | mail@eblum.ch   |
| V      | <b>Designation of States</b>   |   |
| V-1    | <b>Regional Patent</b><br>(other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)   | <p>AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM<br/>ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT</p> <p>EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT</p> <p>EP: AT BE CH&amp;LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR and any other State which is a Contracting State of the European Patent Convention and of the PCT</p> <p>OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT</p> |
| V-2    | <b>National Patent</b><br>(other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)   | <p>AE AG AL AM AT AU AZ BA BB BG BR BY BZ<br/>CA CH&amp;LI CN CO CR CU CZ DE DK DM DZ EC<br/>EE ES FI GB GD GE GH GM HR HU ID IL IN<br/>IS JP KE KG KP KR KZ LC LK LR LS LT LU<br/>LV MA MD MG MK MN MW MX MZ NO NZ OM PH<br/>PL PT RO RU SD SE SG SI SK SL TJ TM TN<br/>TR TT TZ UA UG US UZ VN YU ZA ZM ZW</p>  |

## PCT REQUEST

Original (for SUBMISSION) - printed on 08.04.2002 12:59:38 PM


|               |   |                                       |                             |
|---------------|---|---------------------------------------|-----------------------------|
| V-5           | <b>Precautionary Designation Statement</b><br>In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. |                                       |                             |
| V-6           | <b>Exclusion(s) from precautionary designations</b>   | NONE                                  |                             |
| VI            | <b>Priority claim</b>   | NONE                                  |                             |
| VII-1         | <b>International Searching Authority Chosen</b>   | European Patent Office (EPO) (ISA/EP) |                             |
| VIII          | <b>Declarations</b>   | Number of declarations                |                             |
| VIII-1        | Declaration as to the identity of the inventor  | -                                     |                             |
| VIII-2        | Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent  | -                                     |                             |
| VIII-3        | Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application  | -                                     |                             |
| VIII-4        | Declaration of inventorship (only for the purposes of the designation of the United States of America)  | -                                     |                             |
| VIII-5        | Declaration as to non-prejudicial disclosures or exceptions to lack of novelty  | -                                     |                             |
| IX            | <b>Check list</b>   | number of sheets                      | electronic file(s) attached |
| IX-1          | Request (including declaration sheets)  | 5                                     | -                           |
| IX-2          | Description (excluding sequence listing part)   | 32                                    | -                           |
| IX-3          | Claims  | 2                                     | -                           |
| IX-4          | Abstract  | 1                                     | EZABST00.TXT                |
| IX-5          | Drawings  | 10                                    | -                           |
| IX-7a         | Sub-total number of sheets  | 50                                    |                             |
| IX-6          | Sequence listing part of description  | 9                                     | -                           |
| IX-7          | TOTAL   | 59                                    |                             |
|               | <b>Accompanying items</b>   | paper document(s) attached            | electronic file(s) attached |
| IX-8          | Fee calculation sheet   | ✓                                     | -                           |
| IX-16         | Sequence listing in computer readable form:   |                                       |                             |
| IX-16<br>(-I) | copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application)  | -                                     | 1 Diskette                  |
| IX-17         | PCT-EASY diskette   | -                                     | Diskette                    |

5/5

06052PC

## PCT REQUEST

Original (for SUBMISSION) - printed on 08.04.2002 12:59:38 PM

|       |  |   |
|-------|--|---|
| IX-19 | Figure of the drawings which should accompany the abstract |   |
| IX-20 | Language of filing of the international application        | English   |
| X-1   | Signature of applicant, agent or common representative     |  |
| X-1-1 | Name   | E. BLUM & CO.   |
| X-1-2 | Name of signatory  | Paul Ronchi   |
| X-1-3 | Capacity   | i.v.  |

## FOR RECEIVING OFFICE USE ONLY

|        |   |               |            |
|--------|---|---------------|------------|
| 10-1   | Date of actual receipt of the purported international application   | 09 APRIL 2002 | (09.04.02) |
| 10-2   | Drawings:   |               |            |
| 10-2-1 | Received  |               |            |
| 10-2-2 | Not received  |               |            |
| 10-3   | Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application |               |            |
| 10-4   | Date of timely receipt of the required corrections under PCT Article 11(2)  |               |            |
| 10-5   | International Searching Authority   | ISA/EP        |            |
| 10-6   | Transmittal of search copy delayed until search fee is paid   |               |            |

## FOR INTERNATIONAL BUREAU USE ONLY

|      |  |  |
|------|--|--|
| 11-1 | Date of receipt of the record copy by the International Bureau |  |
|------|--|--|

Enhancer sequence of the 5-aminolevulinic  
acid synthase gene

Technical Field

5

The present invention relates to a transcrip-  
tional enhancer of the 5-aminolevulinic acid synthase  
gene (ALAS1) and to a method for testing chemical com-  
pounds as inducers of heme and/or P450 synthesis.

10

Background Art

Humans are exposed to many foreign compounds  
(xenobiotics) in their diet, in their environment, and as  
15 clinically prescribed drugs (e.g., rifampicin and pheno-  
barbital). In response to these exposures mammals have  
evolved mechanisms to induce proteins involved in xenobi-  
otic detoxification. Metabolism by Phase I enzymes, par-  
ticularly the heme containing monooxygenases cytochromes  
20 P450 is frequently the first line of defense against such  
xenobiotics. The activity of these detoxification enzymes  
leads to limited in vivo half lives of therapeutical  
drugs and consequently to a limited duration of the  
therapeutic effect.

25 Induction of drug-metabolizing enzymes by  
drugs and chemicals includes the transformation of drugs  
to inactive, active or toxic metabolites and has impor-  
tant clinical consequences. These consequences include  
drug-drug interactions and the precipitation of certain  
30 diseases such as the hepatic porphyrias. Induction of 5-  
aminolevulinic acid synthase by drugs, chemicals, hor-  
mones and nutrients is a hallmark of the acute attacks of  
hepatic porphyria, a rare inherited metabolic disease  
characterized by acute attacks of neuropsychiatric symp-  
35 toms.

During the development of new therapeutial  
drugs it is therefore desirable to screen said new active

compounds for their ability to induce detoxification enzymes.

The prior art describes test methods allowing a measurement of xenobiotic induction of degradation enzymes. International patent application WO 99/61622 describes a system for screening potential new drugs for susceptibility to metabolic degradation. Said method is based on a transcriptional enhancer of the human gene P450CYP3A4. Said enhancer is responsible for the transcriptional induction of the CYP3A4 gene by xenobiotic inducers including therapeutic drugs.

WO 99/48915 discloses a method of screening test compounds for their ability to induce CYP3A4 gene expression. The described method is based on the isolation of an orphan nuclear receptor designated human pregnane X receptor (hPXR) that binds e.g. to a rifampicin/dexamethasone response element in the CYP3A4 gene regulatory region. The binding of said hPXR receptor modulates transcription of the CYP3A4 gene. The CYP3A4 enzyme is just one of 55 human CYP enzymes of which many are inducible via similar or different enhancer regions.

Although there exist already test systems allowing an evaluation of the induction of degradation enzymes by xenobiotics such as e.g. new therapeutical drugs, there is still a need for alternative means and methods allowing an easy and inexpensive testing of new therapeutical drugs for their capacity to induce any drug-metabolizing enzyme.

### Disclosure of the Invention

Hence, it is a general object of the invention to provide an isolated nucleic acid sequence which comprises at least a DR-4 nuclear receptor binding site and wherein said nucleic acid sequence functions as transcriptional enhancer of the 5-aminolevulinic acid synthase gene. Activation of said nucleic acid sequence is a



marker for the induction of any cytochrome P450 gene and not just of CYP3A4.

In a preferred embodiment said nucleic acid sequence further comprises a nuclear factor 1 binding site (NF-1) or has the sequence set forth in Seq. Id. No. 1.

The nucleic acid sequence of the present invention which encompasses a nuclear factor 1 binding site preferably comprises a sequence selected from the group consisting of Seq. Id. No. 2 to 7.

In a further preferred embodiment said nucleic acid sequences mediate chemical compound induced transcriptional activation. Said chemical compound is preferably a candidate compound for therapeutical use or a therapeutical drug.

Another object of the present invention is a genetic construct comprising a nucleic acid sequence of the present invention which is operably linked to a nucleic acid encoding a reporter molecule. Said reporter molecule has preferably an enzymatic activity, more preferably said reporter molecule activity can be detected by colorimetric methods, by radioactivity, fluorescence or chemiluminiscence.

Said reporter molecule is preferably selected from the group consisting of luciferase, beta-galactosidase, chloramphenicol acetyltransferase, alkaline phosphatase and green fluorescent protein.

A third object of the present invention is a method for testing compounds for modulation of heme and/or P450 cytochromes synthesis. Said method comprises the following steps: contacting suitable cells comprising a genetic construct of the present invention with a test compound and detecting enhanced/reduced expression and/or transcription of the nucleic acid sequence encoding the reporter gene. The detectable enhanced or repressed reporter gene expression and/or transcription is indicative

of a compound that enhances or represses heme and/or P450 synthesis.

In a preferred embodiment said test compound is a candidate drug for therapeutical use or a therapeutic drug.

In a further preferred embodiment of the present method said enhanced expression of the nucleic acid sequence encoding the reporter gene is detected by colorimetry, fluorescence, radioactivity or chemiluminiscence.

In a particular preferred embodiment said enhanced transcription of the nucleic acid encoding the reporter gene is detected by quantitative PCR.

Preferred cells for the use in a method of the present invention are Leghorn Male Hepatoma (LMH) cells, other hepatoma cells, monkey kidney cells (CV-1, COS-1) or human kidney cells.

In a further aspect the present invention relates to the use of a nucleic acid of the present invention or a fragment thereof for the testing of chemical compounds as modulators of heme and/or P450 synthesis.

The present invention relates furthermore to the use of a genetic construct of the present invention for the testing of chemical compounds as modulators of heme and/or P450 cytochromes synthesis.

25

#### Brief Description of the Drawings

The invention will be better understood and objects other than those set forth above will become apparent when consideration is given to the following detailed description thereof. Such description makes reference to the annexed drawings, wherein:

Figure 1 A shows the isolation of 176bp and 167 bp drug-responsive enhancer sequences within the first 15 kb upstream of the chicken ALAS1 transcription start site by restriction endonuclease digestion and sub-

cloning. Fragments were cloned into the pLucMCS luciferase reporter vector containing an SV-40 promoter;

Figure 1 B shows the DNA sequences of the 176 and 167 bp enhancers. Numbering refers to sequence positions relative to the transcriptional start site of the chicken ALAS1 gene. Solid lines identify DR4 and DR5 NR binding sites. Shaded boxes contain individual half sites. A hatched line marks the NF1 binding site;

Figure 1 C shows reporter gene assays of the fragments. The constructs were transfected together with a transfection-control construct expressing  $\beta$ -galactosidase into LMH cells. Cells were then treated with 600  $\mu$ M PB for 16 h and luciferase assays were performed on the cell extracts. Relative luciferase levels are standardized against cells transfected with vector containing no insert and expressed as fold induction. Experiments were repeated at least three times and data from a representative experiment tested in triplicate are shown here. Error bars represent standard deviations;

Figure 2 shows a comparison of ADRES and mRNA activation by different drugs. Relative luciferase levels are standardized against cells transfected with vector containing no insert and expressed in fold induction. Experiments were repeated at least three times and data from representative experiments tested in triplicate are shown here. Error bars represent standard deviations;

Figure 3 A shows site-directed mutagenesis of the DR4 and DR5 sites within the 176 bp ADRES element. Mutations in the DR4 and DR5 halfsites of the 176 bp sequences were introduced via PCR-based site-directed mutagenesis. Mutations are labeled in the left column and depicted with crosses in the scheme. Relative luciferase levels are standardized against cells transfected with vector containing no insert (control set to 1.0) and expressed as percentages of the 176 ADRES. Experiments were repeated at least three times and data from representati-

ve experiments tested in triplicate are shown here. Error bars represent standard deviations;

Figure 3 B shows site-directed mutagenesis of the DR4 sites within the 167 bp ADRES element. Mutations in the DR4 halvesites of the 167 bp sequence were introduced via PCR-based site-directed mutagenesis. Mutations are labeled in the left column and depicted with crosses in the scheme. The experimental procedure was the same as described in figure 3 A;

Figure 4 A shows a gel-mobility shift assay demonstrating that CXR binds the 176 bp ADRES element. Radiolabelled ADRES wild type (lanes 1-5) and mutant (lanes 6-7) sequences were incubated with *in vitro* transcribed / translated CXR (lanes 3-7), chicken RXR (lanes 2 and 4-7) and anti-RXR antibody (lane 5 and 7), as indicated. Arrows depict the unbound probe, the shifted CXR-RXR-probe complex, and the supershifted CXR-RXR-probe-anti-RXR antibody complex;

Figure 4 B shows gel-mobility shift assay demonstrating that CXR binds the 167 bp ADRES element. Radiolabelled ADRES wild type (lanes 1-5) and mutant (lanes 6-7) sequences were incubated with *in vitro* transcribed / translated CXR (lanes 3-7), chicken RXR (lanes 2 and 4-7) and anti-RXR antibody (lane 5 and 7), as indicated. Arrows depict the unbound probe, the shifted CXR-RXR-probe complex, and the supershifted CXR-RXR-probe-anti-RXR antibody complex;

Figure 5 A shows transactivation of the 176 bp ADRES element by CXR. Cos-1 cells were transfected with constructs containing 4 repeats of the wild type, DR4-1, DR5 and DR4-1/DR5 mutants cloned into the pBLCAT5 vector containing a thymidine kinase minimal promoter. The chicken CXR coding region cloned into the pSG5 expression vector was cotransfected along with a vector expressing pSV  $\beta$ -galactosidase as control. Cells were then treated for 16 h with either drugs or vehicle control and extracts were analyzed for CAT expression normalized

against  $\beta$ -galactosidase levels as described in Materials and Methods. Experiments were repeated at least three times and data from representative experiments tested in triplicate are shown here. All constructs were verified  
5 by sequencing and error bars represent standard deviations;

Figure 5 B shows transactivation of the 167 bp ADRES element by CXR. Cos-1 cells were transfected with constructs containing a single copy of the wild type, DR4-2, DR4-3 and DR4-2/DR4-3 mutants cloned into the  
10 pBLCAT5 vector containing a thymidine kinase minimal promoter. The experimental procedure was the same as described under figure 5B;

Figure 6 shows induction of expanded mouse  
15 core fragments in luciferase reporter gene assay in LMH cells. Inducer Metyrapone 500  $\mu$ M;

Figure 7 shows induction of the mouse 369bp DRES by different drugs;

Figure 8 shows the 369bp mouse DRES sequence  
20 and discovered putative nuclear receptor binding sites;

Figure 9 shows mutation introduced in the DR4 halfsites of the 369bp DRES sequence. The halfsites were mutated individually and both together. Mutated base pairs are underlined and in italics;

25 Figure 10 shows induction of DR4 mutant constructs of mouse 369 DRES in luciferase reporter gene assay in LMH cells;

Figure 11 shows drug-induction of different fragments of the human ALAS1 gene. Fragments were cloned  
30 into the pGL3 luciferase reporter vector (Promega Corp) and tested for inducibility by the prototypical hALAS1 inducers phenobarbital (PB) and propylisopropylacetamid (PIA). Four hours after transfection of LMH cells with the constructs, cells were exposed to the drugs for 24  
35 hours, after which luciferase activity was assayed. Results were normalized for transfection efficiency by as-

saying for activity of co-transfected  $\beta$ -galactosidase.  
Data shown is one representative experiment;

Figure 12 shows that the effect of drugs on  
the ha795 element depends on the presence of a DR-4 mo-  
tif. Within the sequence of the ha795 fragment, a putati-  
ve DR-4 type nuclear receptor response element was found  
by computer analysis. Site-directed mutagenesis of this  
element abolished inducibility of this fragment in repor-  
ter gene assays in LMH cells. Experiments were performed  
as described under figure 8;

Figure 13 shows that a core sequence spanning  
the DR-4 element is sufficient to mediate drug induction  
in LMH cells. From the ha795 fragment, the ha174 fragment  
was derived. It is 174bp in length and within its se-  
quence, the DR-4 response element is contained. Direct  
repeats of the wildtype ha174 or a mutant, where the DR-4  
was destroyed were cloned into the pGL3 reporter vector  
and tested in LMH cells;

## 20 Modes for Carrying Out the Invention

Heme is an essential component in oxygen  
transport and metabolism in living systems. In non-  
erythropoietic cells, the first and rate-limiting enzyme  
in the pathway, 5-aminolevulinic acid synthase (ALAS1),  
regulates its biosynthesis. Under normal physiological  
conditions, free heme levels are low and tightly regu-  
lated, as toxicity can occur with increased cellular con-  
centrations of unincorporated heme. Following administra-  
tion of drugs such as phenobarbital (PB) or other proto-  
typical CYP inducers, heme concentrations are elevated in  
the liver to accommodate the increased levels of heme de-  
pendent enzymes. This is achieved by induction of ALAS1  
and assures an adequate and apparently coordinated supply  
of heme for the generation of functional cytochrome holo-  
proteins such as e.g. cytochromes P450 (CYP).

In the scope of the present invention the inventors have identified and characterised nucleic acid elements in the 5' flanking region of the gene encoding ALAS1 which functions as an enhancer for ALAS1 gene transcription. Said identified nucleic acid element is responsible for chemical compound induced ALAS1 gene transcription.

Said nucleic acid elements comprise at least a DR-4 nuclear receptor binding site. The term "DR-4 nuclear receptor binding site" as used herein refers to a direct repeat-4 hexamer repeat. Such a binding site is characterised by hexamer half sites arranged as direct repeats with a 4 nucleotide separation between half-sites. The half-site has the following canonical sequence AG(T/G)TCA. The term as used herein comprises as well functional equivalents of the canonical sequence i.e. half-site sequence variants which are still able to function as binding sites for nuclear receptors such as e.g. CAR (constitutive androstane receptor)/RXR (retinoid X receptor) heterodimers.

In a preferred embodiment said ALAS1 gene enhancer further comprises a NF-1 binding site. The term "NF-1 binding site" as used herein refers to a DNA element which serves as binding site for members of the nuclear factor-1 family of transcription factors, and said term encompasses functional equivalents thereof i.e. sequence variants which are still able to function as binding sites for members of the nuclear factor 1 (NF1) family of transcription factors. The NF-1 binding site has the following consensus sequence: TGGC(N<sub>4</sub>)GCCA (N= any nucleotide). For a man skilled in the art it is clear that the sequences of the present invention can comprise more than one copy of the above identified binding sites.

In the scope of the present invention the following sequences conferring chemical compound induced ALAS1 gene transcription were characterised: Seq. Id. No. 1 (chicken), Seq. Id. No. 2 (chicken), Seq. Id. No. 3 to

7 (mus musculus) and Seq. Id. No. 8 to 10 (homo sapiens).  
The nucleic acid sequences set forth in Seq. Id. No. 8 to  
10 have been part of a databank before the filing date of  
this application but these three sequences have not been  
5 characterised and their function/ activity has been un-  
know.

It has to be understood that the term nucleic  
acid sequence as used herein encompasses fragments, vari-  
ants or derivatives of the sequences 1 to 10 of the pres-  
10 ent invention. Based on the disclosed enhancer sequences  
of ALAS1 and well known molecular biological methods as  
e.g. described in Sambrook et al., Molecular Cloning: A  
Laboratory Manual, New York: Cold Spring Harbor Labora-  
tory, 2001) a man skilled in the art is able to isolate  
15 further sequences conferring chemical compound induced  
ALAS1 gene transcription/expression.

The construction of a genetic construct of  
the present invention can be done using standard molecu-  
lar biology techniques as described e.g. in Sambrook et  
20 al., Molecular Cloning: A Laboratory Manual, New York:  
Cold Spring Harbor Laboratory, 2001).

The cell used in a test method can be any  
suitable cell allowing the performance of chemical com-  
pound induced assays. A particularly preferred cell line  
25 for the use in a method of the present invention is the  
Leghorn male hepatoma (LMH) cell line. The genetic con-  
struct can be introduced in the cells by well known  
transfection methods such as e.g. chemical transfection,  
elektrotransfection or viral transfection. Said host cell  
30 can express the genetic construct of the invention from a  
genomic locus or from an expression vector. Typically, an  
expression vector comprises the regulatory sequences re-  
quired to achieve transcription and expression in the  
host cell and it may contain necessary sequences required  
35 for plasmid replication in order to exist in an episomal  
state, or it may be designed for chromosomal integration.



A suitable vector is e.g. pGL3LUCpro (Promega) which comprises the gene encoding luciferase.

The method for testing compounds for modulation of heme and/or P450 synthesis of the present invention comprises the following steps: suitable cells harboring a genetic construct of the present invention are contacted with a test compound and an enhanced or repressed reporter gene expression and/or transcription is detected. The detection method of the enhanced or repressed gene transcription/expression is depending on the used reporter gene and can be done at the transcriptional level using e.g. quantitative PCR or by detecting the reporter gene product. Preferred detection methods for the reporter gene product are colorimetric, fluorescence or chemiluminiscence assays such as e.g. luciferase assay, CAT assay or  $\beta$ -galactosidase assay.

The invention is now further described by means of examples:

#### **Isolation and characterization of a drug responsive enhancer of the chicken 5-aminolevulinic acid gene**

A cosmid clone containing an insert approximately 35 kb in length spanning the chicken ALAS1 gene and 15 kb of the 5'-flanking region, was isolated and its sequence analyzed. Three major subclones were generated from the region upstream of the transcriptional start site, including a 3282 bp *SmaI* fragment and 5056 bp and 7973 bp *EcoRI* segments (Fig. 1A). The *SmaI* clone extends from -167 bp to -3449 bp, whereas the *EcoRI* subfragments span the regions from -2347 bp to -7402 bp and -7403 bp to -15376 bp, respectively. These subfragments were cloned into the pLucMCS modified luciferase vector containing an SV40 promoter as described in Materials and Methods. Drug inducibility was measured in transiently transfected LMH cells treated with 600  $\mu$ M PB and compared

with control values. The results revealed the 7973 bp subfragment to be highly inducible with PB, displaying a 28-fold increase in transcriptional activation relative to control values. In comparison, the 5056 bp and 3282 bp subfragments exhibited virtually no transcriptional activation in response to drug treatment (Fig. 1C). The 7973 bp subfragment (-15376 / -7403) was chosen for further analysis and was divided into numerous subclones in the pLucMCS reporter vector resulting in the isolation of 176 bp *Sau3AI-SmaI* and 167 bp *PvuII-HaeIII* elements (Fig. 1A and 1B). These sequences routinely exhibit 25-60 fold induction over control values in reporter gene assays when exposed to PB in LMH cells (Fig. 1C). All other portions of the 7973 bp fragment were also subcloned but displayed no drug response when tested in LMH cells. Because the 176 bp (Seq. Id. No. 2) and 167 bp (Seq. Id. No. 1) fragments retain high drug response regardless of orientation or distance from the promoter they are referred to as aminolevulinic acid synthase drug responsive enhancer sequence (ADRES) elements.

Recent discoveries have implicated NRs in drug mediated enzyme induction (2, 3, 8). For this reason, we scanned the responsive elements for potential nuclear receptor response sites using a computer algorithm based on a weighted nucleotide distribution matrix compiled from published functional hexamer halfsites. Two potential binding sites for orphan NRs were identified in each ADRES element, having two direct repeats with 4 nucleotide (DR4) and 5 nucleotide (DR5) separations between halfsites in the 176 bp sequence and two direct repeats with 4 nucleotide (DR4) separations between halfsites in the 167 bp sequence (Fig. 1B). For clarity, the three DR4 binding sites are labeled according to their occurrence in the gene, with the furthest upstream from the transcription start site called DR4-1 and the closest to the start site DR4-3. The putative DR4-1 is defined by one perfect half-site (AGGTCA) and one imperfect half-

site (AGTTGA) at -14186/-14181 and -14176/-14171 respectively, whereas the DR5 site is characterized by an imperfect upstream half-site (AGCTGA) and a perfect downstream half-site (AGGTCA) at -14251/-14246 and -14240/-14235. In the 167 bp sequence, DR4-2 consists of one imperfect upstream half-site (GGATGA) and one perfect downstream half-site (AGTTCA) at -13563/-13558 and -13553/-13548 and DR4-3 has two imperfect halfsites (GTGTCA and GGGGCA) at -13526/-13521 and -13516/-13511. It is interesting to note that the 176 bp ADRES also contains a putative binding site for nuclear factor 1 which overlaps the DR5, spanning bp -14255 to bp -14242, whereas the 167 bp ADRES does not.

We next wanted to compare ADRES-mediated ALAS1 induction levels from reporter gene assays with stimulation of transcription in a physiological system. Therefore, ALAS1 mRNA levels were quantified in LMH cells cultured in serum-free medium and 16 h of exposure to a variety of chemical inducers and compared to the induction pattern observed with the same compounds in transient transfections of the ADRES (Fig. 2). The compounds examined include PB (600  $\mu$ M) and the PB-like inducers PIA (250  $\mu$ M), glutethimide (500  $\mu$ M), and the potent mouse CYP 2B inducer 1,4-bis[2-(3,5-dichloropyridyl-oxy)]benzene (TCPOBOP) (10  $\mu$ M). In addition, the common CYP3A inducers dexamethasone (50  $\mu$ M), metyrapone (400  $\mu$ M), and 10  $\mu$ M mifepristone (RU-486) were employed for comparison. We were also interested in the effects of 10  $\mu$ M 5-pregnen-3 $\beta$ -ol-20-one-16 $\alpha$ -carbonitrile (PCN) and rifampicin (100  $\mu$ M) due to their species-specific effects on PXR activation and CYP3A induction. Messenger RNA was reverse transcribed and levels of ALAS1 cDNA were quantified using the Taqman real-time PCR quantification system as described in Materials and Methods. PB was a strong inducer of ALAS1 in LMH cells, increasing RNA levels an average of 16 fold relative to basal transcript levels (Fig. 2). This value was chosen to represent 100% induction,

against which all other values are compared. The general inducers PIA and glutethimide, as well as the 3A-specific inducer metyrapone exhibited the strongest effects upon the ADRES elements, stimulating transcription in excess of levels obtained from PB treatment. In comparison, dexamethasone, PCN, RU-486, and rifampicin had minor or no effects on either mRNA levels or ADRES activation. Moreover, the mouse-specific compound TCPOBOP elicited no response in either mRNA transcription or stimulation of the ADRES in reporter assays. When comparing the induction profiles of the two ADRES elements to each other, very few differences are in evidence. The 167 bp (Seq. Id. No. 1) responds to PB with twice the activation when compared to the 176 bp element (Seq. Id. No. 2). Also, the 176 bp has slightly more affinity for glutethimide than metyrapone, whereas the 167 bp element exhibits a stronger response to metyrapone than glutethimide. These experiments indicate a high degree of similarity in the relative activation of the ADRES elements in reporter gene assays to each other and to mRNA transcript levels from chemically induced LMH cells.

Site-specific mutagenesis was used to examine the roles of specific nucleotides within the putative DR5 and DR4 recognition sequences in conferring drug response to the ADRES elements (Fig. 3). Mutant constructs of the DR4 and DR5 core recognition sites destroying the putative NR binding sites were generated as described in Materials and Methods. Briefly, primers were used in conjunction with PCR to convert the 5' and 3' half-sites of the DR5 to *EcoRI* and *PstI* restriction endonuclease sites, respectively. Similarly, the DR4-3 half-sites were converted to *EcoRI* and *NcoI* restriction endonuclease sites. Data from a nucleotide distribution matrix for halfsites developed by M. Podvinec in this laboratory was applied to ascertain that the mutated halfsites least resemble functional halfsites. DR4-1 halfsites were obliterated by converting AGGTCA and AGTTGA halfsites to unconserved

ACTCGA and ATACCA bases, respectively. Similarly, DR4-2 halfsites were both converted from GGATGA and AGTTCA nucleotides to CCCCAC bases. Primers were used to generate constructs mutated at each individual and both NR binding sites within both of the ADRES elements as shown in figure 3.

The modified enhancers were examined for response to 600  $\mu$ M PB in luciferase reporter gene assays and the results are presented in Figure 3. These findings indicate that both the DR5 and DR4 recognition sites in the 176 bp ADRES and both DR4 recognition sites in the 167 bp ADRES element are essential to elicit full drug response. Mutation of the DR5 reduced activity of the 176 bp ADRES element by over 85% from 44 fold to 6.4 fold activation by PB, whereas changes in the DR4-1 limited activation by over 60% from 44 fold to 16 fold stimulation (Fig. 3A). As depicted in Figure 3B, both DR4-2 and DR4-3 sites in the 167 bp ADRES element were found to be required for full activation by PB. Alteration of the DR4-2 site resulted in the reduction of PB response by over 90% from 60 fold to 5.4 fold. Mutations in the DR4-3 site caused PB response to be diminished 75% from 60 to 15 fold induction. These studies demonstrate an essential contribution of the sequences within the putative DR4 and DR5 NR binding sites to PB activation of the ADRES elements.

Because the DR5 overlaps a putative binding site of NF1, a transcription factor that has been implicated in modifying drug induction, we tested the possibility that NF1 confers activation to the 176 bp ADRES element rather than NRs binding to the DR5 (5). A mutant construct converting the putative NF1 site to a consensus avian NF1 binding site, thus destroying the first half-site of the DR5, was generated and tested in luciferase assays. As seen in Figure 3A, the NF1 consensus sequence does not increase the response of the 176 bp ADRES element to drugs. Rather, the induction is decreased by 66

percent from 44 to 15 fold induction, presumably due to the destruction of the DR5 NR binding site. In order to confirm these findings, chicken NF1-A was amplified from a cDNA library generated from LMH cells and cloned into pSG5 expression vector. Coding sequence fidelity was confirmed by sequencing and the construct was co-transfected both in induction experiments in LMH cells and transactivations in Cos-1 cells, resulting in no changes in induction or transactivation.

Recent findings have implicated a number of orphan NRs in drug induction of cytochromes P450 (for reviews, see (6, 10, 11). Our group has successfully cloned and expressed chicken CXR and has demonstrated CXR-RXR interactions with CYP enhancers in electrophoretic mobility shift assays (EMSAs) (2). As the DR4 and DR5 sites clearly contribute to the transcriptional activation exhibited by the ADRES elements, gel-mobility shift assays were used to determine whether CXR might bind the responsive enhancers (Fig. 4). Neither *in vitro* transcribed/translated chicken CXR nor chicken RXR alone bound to the <sup>32</sup>P-radiolabeled 176 bp ADRES (Fig. 4A, lanes 2 and 3) or to the 167 bp ADRES (Fig. 4B, lanes 2 and 3). In contrast, CXR/RXR heterodimers bind the drug responsive enhancers, and these complexes could be supershifted with anti-RXR antibodies (Fig. 4A and 4B, lanes 4 and 5). Nuclear receptor binding to the 167 bp ADRES element was reduced when the double mutant DNA sequences were used, as demonstrated by the reduced band intensities of the shifted and supershifted components (Fig. 4B, lanes 6 and 7). Moreover, the binding of CXR/RXR heterodimers was virtually eliminated when both binding sites in the 176 bp ADRES elements were mutated (Fig. 4A, lanes 6 and 7). These findings demonstrate interactions of CXR/RXR heterodimers with the ADRES elements through the DR4 and DR5 NR binding sites.

In order to confirm the role of CXR in the activation of the ADRES elements, transactivation experi-

ments were done in Cos-1 monkey kidney cells. These cells express RXR but exhibit no induction response under normal conditions. Four copies of the wild type and mutated 176 bp element or a single copy of the mutated and wild type 167 bp element were cloned into the pBLCAT5 plasmid containing a tk minimal promoter as described in Materials and Methods. CAT vectors were used for transactivations rather than luciferase because CAT provided more stable expression and showed higher drug response. These constructs were cotransfected along with a pSG5 expression vector containing the coding sequence for CXR and a  $\beta$ -galactosidase expression construct to correct for variations in transfection efficiency. After 24 h incubation to allow for the expression of CXR, induction of the wild type and mutant sequences was tested with glutethimide, metyrapone and PIA, the three best inducers identified in figure 2. As shown in Figure 5, both the 176 bp and 167 bp ADRES elements are transactivated by CXR. In the 176 bp element, the induction was reduced by 10-25% in the constructs carrying the mutant DR5 NR binding site. The mutations in the DR4-1 binding site reduced the induction by all drugs to less than 1.6 fold. Moreover, the alteration of both NR binding sites in the 176 bp element resulted in the complete elimination of drug response. The 167 bp element was found to respond better to drugs in transactivations than the 176 bp element, thus a single copy was sufficient. The induction of the wild type sequence was strong for all three drugs, ranging from 4.0 to 8.3 fold over uninduced levels (Fig. 5B). The DR4-2 mutants exhibited lower induction after drug exposure, reduced by 58-66% when compared to wild type values. Similarly, the DR4-3 mutant sequences responded to drugs with diminished capacity, exhibiting 55-66% of the 167 bp activity. The double mutant 167 bp element did not respond to drugs, confirming the role of CXR in activating the ADRES elements via the DR4 and DR5 NR binding sites.

## Material and Methods

### Reagents

Dexamethasone, metyrapone (2-methyl-1,2-di-3-pyridyl-propadone), 5-pregnene-3 $\beta$ -ol-20-one-16 $\alpha$ -carbonitrile (PCN) and rifampicin were purchased from Sigma chemical company. Propylisopropylacetamide (PIA) was a gift from Dr. Peter Sinclair (Veterans Affairs Hospital, White River Junction, VT). Glutethimide was purchased from Aldrich. Mifepristone (RU-486) was obtained from Roussel-UCLAF. 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) was generously provided by U. Schmidt (Institute of Toxicology, Bayer, Wuppertal, Germany). Phenobarbital sodium salt (5-ethyl-5-phenyl-barbituric acid sodium salt) was purchased from Fluka. Tissue culture reagents, media, and sera were purchased from Life Technologies. All other reagents and supplies were obtained from standard sources.

### Plasmids

The pGL3LUC luciferase reporter containing an SV40 promoter was purchased from Promega. The reporter plasmid was modified by the addition of the fragment spanning the *Sac*I to the *Xho*I restriction endonuclease sites of the multiple cloning site of the pBluescript SK vector (Stratagene) to the pGL3LUC vector, thus greatly enhancing the cloning versatility of the new pLucMCS reporter. The pBLCAT5 chloramphenicol acetyl transferase reporter vector was described previously (1). Chicken CXR and RXR were cloned into the pSG5 expression vector (Stratagene) as previously reported (2). The pRSV  $\beta$ -galactosidase vector used for normalization of transfection experiments was kindly provided by Anastasia Kralli (Biozentrum, University of Basel, Basel, Switzerland).

### Cosmid Isolation



A specific probe for the ALAS1 gene was generated via PCR using chicken embryo liver genomic DNA as template and forward primer 5'-CGG GCA GCA GGT CGA GGA GA-3' (Seq. Id. No. 31) and reverse primer 5'-CAG GAA CGG GCA TTT TGT AGC A-3' (Seq. Id. No. 32). The probe was <sup>32</sup>P-radiolabeled using the random primer labeling kit (Roche Molecular Biochemicals) according to the manufacturer's instructions. A genomic cosmid library generated from adult male Leghorn chicken liver was purchased from Clontech Laboratories. The ALAS1 probe was used to identify an individual cosmid clone containing the ALAS1 gene and at least 15 kb of 5'-flanking region was isolated and confirmed by sequencing.

#### 15                    Construction of vectors

The cosmid containing the ALAS1 gene and flanking region was digested with *EcoRI* restriction endonuclease and subfragments of the approximately 35 kb of new sequence were cloned into the *EcoRI* site of the pLucMCS vector. Eight fragments ranging in size from 10 kb to 900 bp in length were cloned. In addition, a 3282 bp *SmaI* fragment encoding the ALAS1 promoter region and proximal 5'- flanking region was cloned into pLucMCS. The drug-responsive 8 kb *EcoRI* region was then further subdivided using standard subcloning procedures and restriction endonucleases to isolate the *Sau3AI-SmaI* 176 bp element and the *PvuII-HaeIII* 167 bp element. Single copies of the 176 bp and 167 bp wild type and mutated elements were cloned into pBLCAT5 by excising a 222 bp fragment containing the desired sequences with *BamHI* and *BglII* restriction endonucleases and ligating them into *BamHI*-linearized pBLCAT5 vector. Multiple repeats of the 176 bp wild type and mutant elements were subcloned by inserting the 222 bp fragment 4 times in succession into the *BamHI*-linearized pBLCAT5 vector.

#### Cell Culture

Leghorn Male Hepatoma (LMH) cells were obtained from the American Type Culture Collection and cultivated in 10 cm dishes in Williams E medium supplemented with 10% FCS, 1% glutamine (2mM) and 1% penicillin/streptomycin (50 IU/ml). Dishes coated with 0.1% gelatin were used for routine culture of LMH cells in order to facilitate proper seating of the cells onto the plastic plate surface. For transfections, cells were seeded onto 12-well Falcon 3043 dishes and expanded to 70-80% surface density. Cells were then maintained in serum-free Williams E media for 24 hours and transfected using the FuGENE 6 transfection reagent (Roche Molecular Biochemicals) according to the manufacturers protocol.

#### 15                    Analysis of Reporter Gene Expression

Cells were treated with drugs or vehicle for 16 h and harvested. For luciferase assays, lysis was performed with 200  $\mu$ l Passive Lysis Buffer (Promega) per well and extracts were centrifuged for 1 minute to pellet cellular debris. Luciferase assays were performed on supernatants using the Luciferase Assay kit (Promega) and a Microlite TLX1 luminometer (Dynatech). Relative  $\beta$ -galactosidase activities were determined as described (4). For CAT assays, cells were lysed with 600  $\mu$ l CAT lysis buffer per well and extracts were centrifuged for 1 minute to pellet cellular debris. Assays were performed using a CAT ELISA kit (Roche Molecular Biochemicals) according to the manufacturers protocol.

#### 30                    Site-directed Mutagenesis

Mutations in the putative NR binding sites were introduced into the ADRES elements by PCR using standard overlap techniques. Briefly, subfragments were amplified with overlapping primers carrying the desired mutations and vector primers. These subfragments were then combined and used as template in a second PCR using vector primers to amplify the full-length mutated frag-

ment, which was subsequently digested with appropriate enzymes and cloned into pLucMCS. The forward vector primer was the RV primer 3 and the reverse vector primer was the GL primer 2 within the pGL3 luciferase vector (Promega). All mutations are shown in bold. DR4-1 double mutation constructs were generated with 5'-GGA GGA ACT CGA CAC GAT **ACC** AAC ATA GCA AT-3' forward (Seq. Id. No. 15) and 5'-CTA TGT TGG **TAT** CGT GTC **GAG** TTC CTC CCT G-3' reverse (Seq. Id. No. 16) primers. DR5 double mutants were amplified with 5'-**GAA** **TTC** GCC AAC **TGC** **AGC** CAG GCT GTC C-3' forward (Seq. Id. No. 17) and 5'-CAG CCT GGC **TGC** **AGT** **TGG** **CGA** **ATT** CTC CTC-3' reverse (Seq. Id. No. 18) primers. DR4-2 double mutants were generated with 5'-**CCC** **CAC** GCA **GCC** **CCA** CCG CTC GGC TGA ACT CGT G-3' forward (Seq. Id. No. 19) and 5'-**GTG** **GGG** CTG CGT **GGG** GCA GCA GAG AAA GTT CAG G -3' reverse (Seq. Id. No. 20) primers. DR4-3 double mutants were amplified using a 5'-**GAA** **TTC** ACA GCC **ATG** **GTG** AAG ATC AGC-3' forward (Seq. Id. No. 21) primer and a 5'-**CCA** **TGG** CTG TGA **ATT** CAG TCA CGA G-3' reverse (Seq. Id. No. 22) primer. Avian NF1 consensus sequence was generated using 5'-GTT TAA AGC **TGG** **CAC** TGT CCC AAA-3' (Seq. Id. No. 23) and 5'-CTT TGG CAC AGT **GCC** **AGC** TTT AAA C-3' (Seq. Id. No. 24) forward and reverse primers (9). Following PCR overlap, the products were digested with *Bgl*III and either *Eco*RI or *Not*I restriction endonucleases and cloned into pLucMCS. All constructs were verified by sequencing.

#### Quantitative PCR

LMH cells were plated onto 12-well plates, expanded to 70-80% surface density and incubated in serum-free media for 24 h. Cells were then exposed to either drug or vehicle and RNA was isolated with Trizol reagent (Gibco BRL) according to the manufacturer protocol. One µg of total RNA was reverse transcribed with the Moloney murine leukemia virus reverse transcriptase kit (Roche Molecular Biochemicals). PCR was performed using the Taqman PCR core reagent kit (PE Applied Biosystems)

and transcript levels quantitated with an ABI Prism 7700 sequence detection system (PE Applied Biosystems). Relative transcript levels were determined using the relative quantitation method measuring the  $\Delta\Delta C_t$ . The following

5 primers and probes were used in these reactions. ALAS1: probe, 5'-TTC CGC CAT AAC GAC GTC AAC CAT CTT-3' (Seq. Id. No. 25) ; forward primer, 5'-GCA GGG TGC CAA AAC ACA T-3' (Seq. Id. No. 26); reverse primer, 5'-TCG ATG GAT CAG ACT TCT TCA ACA-3' (Seq. Id. No. 27). Glyceraldehyde-3-

10 phosphate dehydrogenase (GAPDH): probe, 5'-TGG CGT GCC CAT TGA TCA CAA TTT-3' (Seq. Id. No. 28); forward primer, 5'-GGT CAC GCT CCT GGA AGA TAG T-3' (Seq. Id. No. 29); reverse primer, 5'-GGG CAC TGT CAA GGC TGA GA-3' (Seq. Id. No. 30). Transcript levels were measured in separate

15 tubes and GAPDH values were used for normalization of ALAS1 values.

#### Gel mobility-shift assays

Chicken CXR and RXR proteins were expressed

20 using the TNT T7 Quick Coupled Translation System (Promega) according to the manufacturers protocol. Probes were labeled by Klenow reaction in the presence of radiolabeled [ $\alpha$ - $^{32}$ P]ATP and purified over a Biospin 6 chromatography column. A volume of labeled oligonucleotide corresponding to 100,000 cpm was used for each reaction in 10

25 mM Tris-HCL (8.0) / 40 mM KCl / 0.05% Nonidet P40 / 6% glycerol (vol./vol.) / 1 mM DTT containing 0.2  $\mu$ g of poly(dI-dC) and 2.5  $\mu$ l *in-vitro* synthesized proteins as described previously (2, 7). To test for supershifts, 0.5

30  $\mu$ l monoclonal anti-mouse-RXR rabbit antibody (kindly provided by P. Chambon, Université Louis Pasteur, Illkirch, France) were added to the reaction mix. This antibody has been previously tested for interactions with chicken RXR in Western blots (data not shown). The reaction mix was

35 incubated for 20 min at room temperature and electrophoresed on a 6% polyacrylamide gel in 0.5X Tris / borate /EDTA buffer followed by autoradiography.

### Transactivations

Experiments to determine the contribution of the nuclear receptor CXR to the induction of ALAS-1 were tested in Cos-1 monkey kidney cells (generously provided by A. Kralli, Biozentrum, University of Basel, Basel, Switzerland) according to methods previously described (2). Briefly, cells were expanded for three days on 10 cm Falcon 3003 dishes in DMEM/F12 medium (Gibco BRL) without phenol red supplemented with 10% charcoal-stripped FBS. Cells were then plated onto 6-well dishes and expanded overnight to approximately 30% density. Cells were then rinsed with PBS and maintained for transfection in Optimem (Gibco BRL) without further additions. Transfection of 1 µg reporter plus 800 ng of pSV β-galactosidase construct and 50 ng of CXR expression vector was performed using 3ml of LipofectAMINE (Invitrogen) per well, according to the manufacturer protocol. After 24 h incubation, cells were rinsed with PBS and DMEM/F12 containing 10% delipidated/charcoal-stripped FBS containing either drugs or vehicle control was added. After 16 hours induction, cells were rinsed with PBS and lysed in 600 µl CAT lysis buffer and assayed for CAT enzyme using the CAT-ELIZA kit (Roche Molecular Biochemicals). CAT levels were then normalized against β-galactosidase levels to compensate for variations in transfection efficiency.

### **Isolation and characterisation of a drug responsive Enhancer of the mouse 5-aminolevulinic acid gene**

#### Cloning of the 5' flanking region of mALAS1

As only several hundred base pairs sequence information of mALAS1 were known, the strategy of isolating 5' flanking region was "chromosomal walking" by southern blotting. For this purpose two bacterial artificial chromosome (BAC) clones termed 113 and 266 were used

(BAC 113d22 and 266n18, mouse C57 B/6 from Genome Systems Inc., St. Louis, MO, USA). By application of said method four different clones, spanning about 17 kb of flanking region were identified. Of these clones a 2.6 kb fragment  
5 was "inducible" in reporter gene assays.

The 2.6 kb HindIII fragment (-14.7kb to -17.3kb) was cloned as follows: 3µg BAC 266 were digested with HindIII over night. A 0.7% gel was run for 6 hours at 90V and the 2.6 kb band was extracted and ligated to  
10 HindIII cut and dephosphorylated, gel-purified pBS bluescript (Stratagene, La Jolla, California, USA) and heat-shock transformed. Subcloning into pGL3LUCpro + MCS was done using EcoRI and KpnI, so that the fragment was in forward direction. In luciferase reporter assay using  
15 a LMH (Leghorn male hepatoma) cell system said construct showed drug inducibility.

Identification of drug responsive enhancer sequence (DRES) in the 2.6 kb HindIII fragment

20

The 2.6 kb fragment was completely sequenced. The fragment has a length of 2604bp. For easy orientation, numbering was given starting at 1 for the 5' end of said fragment. The following fragments were amplified using the 2.6 kb fragment as template: 280bp fragment (398  
25 to 677) (Seq. Id. No. 4), 321bp fragment (398 to 718) (Seq. Id. No. 5), 328bp fragment (350 to 677) (Seq. Id. No. 6) and 369bp fragment (350 to 718) (Seq. Id. No. 7). The following primer pairs were used:

30 280bp fragment: mALAS-16.6FwdKpn (Seq. Id. No. 11) and mALAS-16.35rvXhoI (Seq. Id. No. 12).  
328bp fragment: mALAS-16.65fwdKpn (Seq. Id. No. 13) and mALAS-16.35rvXhoI (Seq. Id. No. 12).  
321bp fragment: mALAS-16.6fwdKpn (Seq. Id.  
35 No. 11) and mALAS-16.3rvXhoI (Seq. Id. No. 14).  
369bp fragment mALAS-16.65fwdKpn (Seq. Id. No. 13) and mALAS-16.3rvXhoI (Seq. Id. No. 14).

A 175bp fragment (441 to 615) (Seq. Id. No. 3) was isolated by digesting the 2.6kb fragment with SacI/XbaI. All fragments were subcloned in the pGL3LUCpro + MCS vector and the resulting constructs tested for inducibility in LMH reporter gene assay (Fig. 6). All five fragments showed enhanced induction with as inducer Metyrapone 500µM. The 369bp fragment was termed Drug responsive enhancer sequence DRES.

The 369bp DRES sequence and discovered putative nuclear receptor binding sites is shown in figure 8. Putative nuclear receptor binding sites were discovered by MatInspector using a core similarity of 0.8 and matrix similarity of 0.85. Putative binding sites include: upstream stimulatory factor (USF), activator protein 1/ 4 (AP1/ AP4), nuclear factor 1 (NF-1), CAR/ CXR/ PXR (DR4), ets-1, estrogen receptor (ER), RAR-related orphan receptor alpha1 (RORα1), PPAR (DR1), nuclear factor κ B (NFκB), c-Rel, sterol response element binding protein (SREBP), stimulatory protein 1 (SP1). SacI and XbaI are the restriction sites of the 175bp core fragment. Bold arrows indicate 5' and 3' ends of the clones from expanding the core SacI/ XbaI fragment.

#### Drug induction pattern of 369bp DRES in LMH luciferase reporter gene assay

To compare the 369bp DRES to other inducible fragments, a series of different drugs was used as inducers: clothrimazole (Clo, 10µM), dexamethasone (Dex, 50µM), glutethimide (GE, 500µM), metyrapone (Met, 500µM), phenobarbital (PB, 500µM), PCN (10µM), propylisopropylacetamide (PIA, 250µM), rifampicin (Rif, 10µM), RU486 (10µM), TCPOBOP (10µM).

Figure 7 shows induction of the 369bp DRES by different drugs. Data shown is from two independent experiments. As it was already observed for the 2.6kb HindIII

clone , metyrapone is the strongest inducer, together with glutethimide and PIA.

#### Mutagenesis of the DR4

5 All experiments done so far, showed that the region containing the DR4 was absolutely required to get any induction at all. To show the direct involvement of the DR4, it was mutated (in the 369bp context) in the following way:

10 The DR4 halvesites were mutated individually and both together (see figure 9). Mutated base pairs are underlined and italic.

To have convenient analysis tools for successful mutagenesis, the NR1 halvesite was mutated into a EcoRI site and the NR2 halvesite into a PstI site.

15

#### Mutagenesis/cloning

In a first mutagenesis, each hexamer halvesite was mutated individually. The first PCR was performed using rvp3 plasmid and DR4mt1rv (Seq. Id. No. 33) and glp2 plasmid and DR4mt1fwd (Seq. Id. No. 34) [DR4mt1], DR4mt2rv (Seq. Id. No. 35) and DR4mt2fwd (Seq. Id. No. 36) [DR4mt2] primer pairs, using the 369bp-LUC clone as template. PCR was run out on 1.5% agarose gel and bands were extracted. The second PCR was performed using the PCR products from the first PCR as template (1µl out of 20µl for each product) and running a PCR with the external primer rvp3 and glp2. The PCR was run out on a 1.2% agarose gel and the bands were extracted. Then, a KpnI/XhoI digestion was performed on that fragment, and after purification directly ligated to KpnI/ XhoI cut pGL3LUCpro + MCS (no gel separation of bands required because after digestion there was only one fragment with the compatible sticky ends for cloning) and heat-shock transformed. Minipreps of DNA were analysed by KpnI/ XhoI digestion (insert) and XhoI/ EcoRI (DR4mt1, check for mutation) or XhoI/ PstI (DR4mt2, check for mutation) dige-

20

25

30

35



stion. Finally, clones were sequenced to confirm desired mutation and no other bp mutations.

In a second step, both halvesites were mutated. For the double mutant DR4mt1mt2, procedure was like above, only that the 369DR4mt2-LUC was taken as template for the first PCR and that the primers DR4mt2mt1fwd (Seq. Id. No. 37) and DR4mt2mt1rv (Seq. Id. No. 38) were used. This construct is shortly termed 369DR4mut-LUC.

#### 10 Inducibility in LMH reporter gene assay

Figure 10 shows induction of DR4 mutant constructs of mouse 369 DRES in luciferase reporter gene assay in LMH cells. As inducer metyrapone 500µM was used. Data shown is from three independent experiments.

15

#### **Drug regulation of the human housekeeping ALA-synthase (ALAS1) gene**

Using a computer-assisted screening approach and sequence information publicly available, several regions of the 5' flanking region of the ALAS1 were defined as potential mediators of drug-induction of the human housekeeping ALAS gene via nuclear receptors. The defined regions were isolated from a BAC clone containing 30kb of the upstream region of this gene and introduced into a reporter vector containing the firefly luciferase gene as a reporter for gene activation. These constructs were tested in LMH chicken hepatoma cells, the only known continuously dividing cell line retaining drug-mediated induction.

30

In these initial screening approaches, two regions were defined which responded to prototypic inducer drugs.

The better-characterized of these regions was called hA795 (Seq. Id. No. 9) and lies approximately 20kb upstream from the transcriptional start site. By dissecting this fragment, we were able to define a short ele-

35

ment, 174bp (Seq. Id. No. 8) in size, which is sufficient to confer induction in LMH cells. The element was termed hA174. Within this hA174 fragment, a DR-4 type nuclear receptor recognition site was found to be necessary for drug induction in site-directed mutagenesis experiments.

The second drug-inducible fragment was called hA8 (Seq. Id. No. 10), is 917 bp in length and is located approximately 16kb upstream from the transcriptional start site. It contains at least predicted DR-3 and DR-4-type nuclear receptor response elements.

In transactivation assays in a heterologous cell line (monkey kidney CV-1 cells) and human hepatoma HepG2 cells, we assessed which nuclear receptor conveys the observed activation. The two candidate receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) were tested on these fragments. With both fragments and the hA174 subfragment, induction by human PXR and activation by mouse and human CAR was observed. The mCAR induced activity could be repressed to approximately 50% by the inverse agonist 3 $\alpha$ -androstanol and this repression was reversible by the direct agonist TCPOBOP (1,4-bis[2-(3,5-dichloropyridyloxy)]benzene).

## Results

### Drug-induction of different fragments of the human ALAS1 gene.

Fragments were cloned into the pGL3 luciferase reporter vector (Promega Corp) and tested for inducibility by the prototypical hALAS1 inducers phenobarbital (PB) and propylisopropylacetamid (PIA). Four hours after transfection of LMH cells with the constructs, cells were exposed to the drugs for 24 hours, after which luciferase activity was assayed. Results were normalized for transfection efficiency by assaying for activity of co-transfected  $\beta$ -galactosidase. Data shown is one representative experiment (Figure 11).

The effect of drugs on the hA795 element depends on the presence of a DR-4 motif.

Within the sequence of the hA795 fragment (Seq. Id. No. 9), a putative DR-4 type nuclear receptor response element was found by computer analysis. Site-directed mutagenesis of this element abolished inducibility of this fragment in reporter gene assays in LMH cells. Experiments were performed as described above (Figure 12).

10

A core sequence spanning the DR-4 element is sufficient to mediate drug induction in LMH cells.

From the hA795 fragment, the hA174 fragment was derived. It is 174bp in length and within its sequence, the DR-4 response element is contained. Direct repeats of the wildtype hA174 or a mutant, where the DR-4 was destroyed were cloned into the pGL3 reporter vector and tested in LMH cells (Fig. 13). Data is from one representative experiment.

20

The abbreviations used are: ALAS, 5-aminolevulinic acid synthase; ADRES, aminolevulinic acid drug responsive enhancer sequence; PB, phenobarbital; DR, hexamer half-site direct repeat; h, hours; bp, basepairs; LMH, leghorn male hepatoma; kb, kilobases; NF1, nuclear factor 1; CYP, cytochrome(s) P450; CXR, chicken xenobiotic receptor; PXR, pregnane X receptor; CAR, constitutive androstane receptor; RXR, 9-cis-retinoic acid receptor; PIA, propylisopropylacetamide; PCN, 5-pregnen-3 $\beta$ -ol-20-one-16 $\alpha$ -carbonitrile; TCPOBOP, 1,4-bis[2-(3,5-dichloropyridyl-oxy)]benzene; LUC, luciferase; mifepristone, RU-486; clotrimazole, 1-[o-chlorotrityl]-imidazole; EMSA, electrophoretic mobility shift assay; cpm, counts per minute; FCS, fetal calf serum.

30

While there are shown and described presently preferred embodiments of the invention, it is to be distinctly understood that the invention is not limited

35

thereto but may be otherwise variously embodied and practiced within the scope of the following claims.

## References

1. Boshart, M., M. Kluppel, A. Schmidt, G. Schutz, and B. Luckow. 1992. Reporter constructs with low background activity utilizing the cat gene. *Gene* 110:129-30.
2. Handschin, C., M. Podvinec, and U. A. Meyer. 2000. CXR, a chicken xenobiotic-sensing orphan nuclear receptor, is related to both mammalian pregnane X receptor (PXR) and constitutive androstane receptor (CAR). *Proc Natl Acad Sci U S A* 97:10769-74.
3. Honkakoski, P., I. Zelko, T. Sueyoshi, and M. Negishi. 1998. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. *Mol Cell Biol* 18:5652-8.
4. Iniguez-Lluhi, J. A., D. Y. Lou, and K. R. Yamamoto. 1997. Three amino acid substitutions selectively disrupt the activation but not the repression function of the glucocorticoid receptor N terminus. *J Biol Chem* 272:4149-56.
5. Kim, J., G. Min, and B. Kemper. 2001. Chromatin assembly enhances binding to the CYP2B1 Phenobarbital-responsive unit (PBRU) of nuclear factor 1, which binds simultaneously with constitutive androstane receptor (CAR)/retinoid X receptor (RXR) and enhances CAR/RXR-mediated activation of the PBRU. *J Biol Chem* 276:7559-7567.
6. Kliewer, S. A., J. M. Lehmann, and T. M. Willson. 1999. Orphan nuclear receptors: shifting endocrinology into reverse. *Science* 284:757-60.
7. Kliewer, S. A., J. T. Moore, L. Wade, J. L. Staudinger, M. A. Watson, S. A. Jones, D. D. McKee, B. B. Oliver, T. M. Willson, R. H. Zetterstrom, T. Perlmann, and J. M. Lehmann. 1998. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. *Cell* 92:73-82.

8. Lehmann, J. M., D. D. McKee, M. A. Watson, T. M. Willson, J. T. Moore, and S. A. Kliewer. 1998. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause  
5 drug interactions. J Clin Invest 102:1016-23.

9. Rupp, R. A., U. Kruse, G. Multhaup, U. Gobel, K. Beyreuther, and A. E. Sippel. 1990. Chicken NFI/TGGCA proteins are encoded by at least three independent genes: NFI-A, NFI-B and NFI-C with homologues in  
10 mammalian genomes. Nucleic Acids Res 18:2607-16.

10. Savas, U., K. J. Griffin, and E. F. Johnson. 1999. Molecular mechanisms of cytochrome P-450 induction by xenobiotics: An expanded role for nuclear hormone receptors. Mol Pharmacol 56:851-7.

15 11. Waxman, D. J. 1999. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369:11-23.

Claims

1. An isolated nucleic acid sequence comprising at least a DR-4 nuclear receptor binding site wherein  
5 said nucleic acid sequence functions as transcriptional enhancer of the 5-aminolevulinic acid synthase gene.

2. The nucleic acid sequence of claim 1 with the proviso that said sequence does not comprise a sequence set forth in Seq. Id. No. 8 to 10.

10 3. The nucleic acid sequence of claim 1 or 2, wherein said sequence comprises the sequence set forth in Seq. Id. No. 1.

4. The nucleic acid sequence of claim 1 or 2, wherein said nucleic acid sequence further comprises a  
15 nuclear factor 1 binding site (NF-1).

5. The nucleic acid sequence of anyone of claims 1 to 4, wherein said nucleic acid sequence mediates chemical compound induced transcriptional activation.

20 6. The nucleic acid sequence of claim 4, wherein said chemical compound is a candidate compound for therapeutical use or a drug.

7. The nucleic acid sequence of anyone of claims 1,2 and 4-6, wherein said sequence comprises a sequence selected from the group consisting of Seq. Id. No.  
25 2-7.

8. A genetic construct comprising a nucleic acid sequence of anyone of claims 1-7 operably linked to a nucleic acid encoding a reporter molecule.

30 9. The genetic construct of claim 8, wherein said reporter molecule has an enzymatic activity.

10. The genetic construct of claim 9, wherein said reporter molecule activity can be detected by colorimetry, radioactivity, fluorescence or chemiluminiscence.

35 11. The genetic construct of anyone of claims 8-10, wherein said reporter molecule is selected from the group consisting of luciferase, beta-galactosidas, chlor-

amphenicol acetyltransferase, alkaline phosphatase and green fluorescent protein.

12. A method for testing compounds for modulation of heme and/or P 450 cytochromes synthesis comprising contacting suitable cells comprising a genetic construct according to claims 8-11 with a test compound and detecting enhanced or repressed expression and/or transcription of the nucleic acid sequence encoding the reporter gene.

10 13. The method of claim 12, wherein said compound is a candidate drug for therapeutical use or a drug.

14. The method of claim 12 or 13, wherein enhanced expression of the nucleic acid sequence encoding the reporter gene is detected by a colorimetry, fluorescence, radioactivity or chemiluminiscence.

15 15. The method of anyone of claims 12-14, wherein enhanced transcription of the nucleic acid encoding the reporter gene is detected by quantitative PCR.

20 16. The method of anyone of claims 12 to 15, wherein said cells are Leghorn Male Hepatoma (LMH) cells, other hepatoma cells, monkey kidney cells (CV-1, COS-1) or human kidney cells.

17. Use of a nucleic acid of anyone of claims 1-7 for the testing of chemical compounds as modulators of heme and/or P450 cytochromes synthesis.

18. Use of a genetic construct of anyone of claims 8-11 for the testing of chemical compounds as modulators of heme and/or P450 cytochromes synthesis.




Abstract

Nucleic acid sequences mediating chemical compound induced 5-aminolevulinate synthase gene (ALAS1) expression are disclosed. Said sequences comprise at least a DR-4 binding site. Furthermore, in vitro methods for testing chemical compounds for modulation of heme and/or P 450 cytochromes synthesis are described.

2/10

Fig. 2



3/10

Fig. 3A





Fig. 3B



4110

Fig. 4B





Fig. 4A



5/10

Fig. 5A





Fig. 5B



6 / 10

Fig. 6






Fig. 7



7110

Fig. 8




8/10

Fig. 9

|            | DR-4 Sequence                    |     |
|------------|----------------------------------|-----|
|            | NR1                              | NR2 |
| WT         | ←                                | ←   |
|            | TGCACTGCCTTGGCCT                 |     |
| DR4 mt1    | <u>GAATTC</u> GCCTTGGCCT         |     |
| DR4 mt2    | TGCACTGCCT <u>CTGCAG</u>         |     |
| DR4 mt1mt2 | <u>GAATTC</u> GCCT <u>CTGCAG</u> |     |


Fig. 10





9/10

Fig. 11



10/10

Fig. 12





Fig. 13



## SEQUENCE LISTING

<110> University Basel  
 <120> Enhancer sequence of the 5-aminolevulinic synthase gene  
 <130> 06052PC  
 <160> 38  
 <170> PatentIn version 3.1  
 <210> 1  
 <211> 167  
 <212> DNA  
 <213> Gallus gallus  
 <400> 1  
 ctgcctccag tcctgaactt tctctgctgg gatgagcaga gttcacgctc ggctgaactc 60  
 gtgactgtgt caacaggggg catgaagatc agcaccaggc aaaggtgagc ggagtgcaca 120  
 agaatgaggc agagaccttt gggacaaaga gttccccacc cgtgggg 167  
 <210> 2  
 <211> 176  
 <212> DNA  
 <213> Gallus gallus  
 <400> 2  
 gggctccatc ggcctcttca gggtattgct atgttcaact cgtgtgacct tcctccctgt 60  
 tttcaagggt ctgataacaa acttctagga cagcctgggtg acctttggct cagcttcctc 120  
 tttaaactcc ggtggccttt gcttcattgc ctagttgtta cccagcagta aagatc 176  
 <210> 3  
 <211> 175  
 <212> DNA  
 <213> Mus musculus  
 <400> 3  
 tgagctcatc aggttcctgg tggagagctg ggtgaaccga gttcgtttgc actgccttgg 60  
 cctgtgtgtg gcttcaggaa caggatcatg tccaggattt aggacacagg ttagctgata 120  
 aggcccatgg agccggtgat atgaccgcga gggcactcc ctctgccccaa gtcta 175  
 <210> 4  
 <211> 280  
 <212> DNA  
 <213> Mus musculus  
 <400> 4  
 agtccagtca gaaccttctg gcttctgcc ttagacagcc tatgagctca tcaggttcct 60  
 ggtggagagc tgggtgaacc gagttcgtt gcactgcctt ggcctgtgtg tggcttcagg 120  
 aacaggatcat gctccaggat ttaggacaca ggtagctga taaggcccat ggagccggtg 180  
 atatgaccgc cagggtcact ccctctgcc aagtctagat acttgtttcc ctctttagac 240

tccagatcaa ggactccaga tctgtcatgg actcagaaaa 280

<210> 5  
 <211> 321  
 <212> DNA  
 <213> Mus musculus

<400> 5  
 agtccagtca gaaccttctg gcttctgcca tgagacagcc tatgagctca tcaggttcct 60  
 ggtggagagc tgggtgaacc gagttcgttt gcactgcctt ggcctgtgtg tggcttcagg 120  
 aacaggatcat gctccaggat ttaggacaca ggtagctga taaggcccat ggagccggtg 180  
 atatgacccg cagggtcact ccctctgccc aagtctagat acttgtttcc ctctttagac 240  
 tccagatcaa ggactccaga tctgtcatgg actcagaaaa cccccagta ccaccacc 300  
 cccgctgctc cctcctatga t 321

<210> 6  
 <211> 328  
 <212> DNA  
 <213> Mus musculus

<400> 6  
 gtggctgggt tgggatggga tgggaaggct tgtgtctctc tgattcctag tccagtcaga 60  
 accttctggc ttctgccatg agacagccta tgagctcatc aggttcctgg tggagagctg 120  
 ggtgaaccga gttcgtttgc actgccttgg cctgtgtgtg gcttcaggaa caggatcatgc 180  
 tccaggattt aggacacagg ttagctgata aggcccatgg agccggtgat atgaccgcga 240  
 gggtcactcc ctctgcccga gtctagatac ttgtttccct ctttagactc cagatcaagg 300  
 actccagatc tgtcatggac tcagaaaa 328

<210> 7  
 <211> 369  
 <212> DNA  
 <213> Mus musculus

<400> 7  
 gtggctgggt tgggatggga tgggaaggct tgtgtctctc tgattcctag tccagtcaga 60  
 accttctggc ttctgccatg agacagccta tgagctcatc aggttcctgg tggagagctg 120  
 ggtgaaccga gttcgtttgc actgccttgg cctgtgtgtg gcttcaggaa caggatcatgc 180  
 tccaggattt aggacacagg ttagctgata aggcccatgg agccggtgat atgaccgcga 240  
 gggtcactcc ctctgcccga gtctagatac ttgtttccct ctttagactc cagatcaagg 300  
 actccagatc tgtcatggac tcagaaaacc cccagtagc accccacccc cgctgctccc 360  
 tcctatgat 369

<210> 8  
 <211> 174  
 <212> DNA

<213> Homo sapiens

<400> 8  
 gcgcaaagtc aacacaagcc tctccaccgt gtgtccatgt ttatgtgtat gcgctgtgcc 60  
 ccgtcatgcc acctggacgc agggactcca gtgacctctc cttgcacaag cctctgctgg 120  
 tttgggaaag attggcatga catcagccaa gctctggcct tgccctttttt ccct 174

<210> 9

<211> 800

<212> DNA

<213> Homo sapiens

<400> 9  
 caggcgcaaa gtcaacacaa gcctctccac cgtgtgtcca tgtttatgtg tatgcgctgt 60  
 gccccgtcat gccacctgga cgcagggact ccagtgaacct ctcccttgac aagcctctgc 120  
 tggtttggga aagattggca tgacatcagc caagctctgg ccttgcccttt tttccctccc 180  
 ggaacccggc tggctcaaga tctgagccgt ggatctgcac ccactttggg gagttcctgc 240  
 ccttgggcta gagtagaggc caagagtcaa agtgtggtgg gggctgaggc agcaggatcg 300  
 cttgagccca ggagttcaag gttagagtta tgtttgcac actgcattcc agcctgggta 360  
 agagagcgag accctgcctc aaaaaaaaaa aaaaaaaaaa aaaaagagtg gtgggggtag 420  
 ggacagggag atgaggaagg ccctacagtg gagaaagcac caggaccaga acccagccct 480  
 cccttgctctg aatcttgctg cccacaggag cctggacagt ggccagggaa ggttcgaatg 540  
 ccacacaggt gagcttggcc tctgctctgt aggcagtggg aagtgctggg agttgggcat 600  
 tcctgtgagg cgcatagtca acattgtgag tagggctgga tgcgagctg tgagagggaa 660  
 actagaagct ggaacatcta caggaggctt ttaagagaag cagagcggcc aggtgcagtg 720  
 gctgacacct gtaatcccag cactttgggt ggccgagggg gtcagaacac ttgaggtcag 780  
 gagttcgaga ccagggtgac 800

<210> 10

<211> 935

<212> DNA

<213> Homo sapiens

<400> 10  
 cacggtacca caggaggcaa aggaccacc atggaatcca cccaggaggg ccaggacagg 60  
 ggactcaggg gcctcagcct gcactcacct gctcagcaga gctgagctca gggcataacg 120  
 tcagcttcct gggcagaaga gctgccaaaa tcaaagcttt gctagtcaga aaattccttg 180  
 ggaatgttga gcaaggccac cactgacatc atgtgcaa atcgcagacag cctctgcacc 240  
 taaggctact cagacccaca gccttggtc gatgggggtgg cagactctgt atgccaccag 300  
 cacaccacc cacagggcag aggggtcagg acatagaatc agacaggccc cagggacccc 360  
 agtgaagatt ataggcagcc attccccact caacagagga gaaggtcaga gccaaagtctg 420

acattccccc atccccctctc cataacaccc atgcatctgg cagtcagaca ggcctaagct 480  
 aaacctttcc cccccagcta cccaccaggg tcatcccaa gccaggtcag ggccaatgga 540  
 gggtgggggtg gagaagacag gcttggccct atttcctgcc caactcagaa ccttctgggt 600  
 tctgccacag gatgccttgc aagcttatcg gggtcactgt gggcagctgg gtgagctaag 660  
 ttcatctgtg ctgccgtgac ctctgtgcag atgcatcaag aacacagagt gctccgggggt 720  
 taggatgagg gcagcgctga taaggttcat ggaaccagt acagagcaca cagctgcccc 780  
 cagagtcact cccctgtgcc ccagcctgga cacctcagct ccctctcaac cccttcccg 840  
 ggtgctagat gtatatggga ccagaaagcc ccctctgtgt cctcctgtgt gagagcccag 900  
 ctgcttaggt gtttgtgact ctgggcctcg agggg 935

<210> 11  
 <211> 25  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Forward PCR primer

<400> 11  
 ggggaccagt ccagtcagaa ccttc 25

<210> 12  
 <211> 27  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Reverse PCR primer

<400> 12  
 ccgctcgagt tttctgagtc catgaca 27

<210> 13  
 <211> 26  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Forward PCR primer

<400> 13  
 ggggtaccgt ggctgggttg ggatgg 26

<210> 14  
 <211> 27  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Reverse PCR primer

<400> 14  
 ccgctcgaga tcataggagg gagcagc 27

<210> 15  
 <211> 32  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> forward PCR primer  
  
 <400> 15  
 ggaggaactc gacacgatac caacatagca at 32  
  
 <210> 16  
 <211> 30  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> reverse PCR primer  
  
 <400> 16  
 ctatgttggt atcgtgtcga gttcctccct 30  
  
 <210> 17  
 <211> 28  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> forward PCR primer  
  
 <400> 17  
 gaattcgcca actgcagcca ggctgtcc 28  
  
 <210> 18  
 <211> 30  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> reverse PCR primer  
  
 <400> 18  
 cagcctggct gcagttggcg aattctcctc 30  
  
 <210> 19  
 <211> 33  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> forward PCR primer  
  
 <400> 19  
 ccccacgcag ccccaccgct cggctgaact cgt 33  
  
 <210> 20  
 <211> 34  
 <212> DNA

<213> artificial sequence  
 <220>  
 <223> reverse PCR primer  
 <400> 20  
 gtggggctgc gtggggcagc agagaaagtt cagg 34

<210> 21  
 <211> 27  
 <212> DNA  
 <213> artificial sequence  
 <220>  
 <223> forward PCR primer  
 <400> 21  
 gaattcacag ccatggtgaa gatcagc 27

<210> 22  
 <211> 25  
 <212> DNA  
 <213> artificial sequence  
 <220>  
 <223> reverse PCR primer  
 <400> 22  
 ccatggctgt gaattcagtc acgag 25

<210> 23  
 <211> 24  
 <212> DNA  
 <213> artificial sequence  
 <220>  
 <223> forward PCR primer  
 <400> 23  
 gtttaaagct ggcactgtcc caaa 24

<210> 24  
 <211> 25  
 <212> DNA  
 <213> artificial sequence  
 <220>  
 <223> reverse PCR primer  
 <400> 24  
 ctttggcaca gtgccagctt taaac 25

<210> 25  
 <211> 27  
 <212> DNA  
 <213> Artificial sequence  
 <220>  
 <223> Probe



<400> 25  
 ttccgccata acgacgtcaa ccatctt 27

<210> 26  
 <211> 19  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> forward PCR primer

<400> 26  
 gcagggtgcc aaaacacat 19

<210> 27  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> reverse PCR primer

<400> 27  
 tcgatggatc agacttcttc aaca 24

<210> 28  
 <211> 24  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> Probe

<400> 28  
 tggcgtgccc attgatcaca attt 24

<210> 29  
 <211> 22  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> forward PCR primer

<400> 29  
 ggtcacgctc ctggaagata gt . 22

<210> 30  
 <211> 20  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> reverse PCR primer

<400> 30  
 gggcactgtc aaggctgaga 20

<210> 31

<211> 20  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> Forward PCR primer  
  
 <400> 31  
 cgggcagcag gtcgaggaga 20  
  
 <210> 32  
 <211> 22  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> reverse PCR primer  
  
 <400> 32  
 caggaacggg cattttgtag ca 22  
  
 <210> 33  
 <211> 27  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> reverse PCR primer  
  
 <400> 33  
 aggccaggcg aattcaacga actcggt 27  
  
 <210> 34  
 <211> 27  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> forward PCR primer  
  
 <400> 34  
 cgagttcggt gaattcgct tggcctg 27  
  
 <210> 35  
 <211> 26  
 <212> DNA  
 <213> artificial sequence  
  
 <220>  
 <223> forward PCR primer  
  
 <400> 35  
 gccacacacc tgcagaggca gtgcaa 26  
  
 <210> 36  
 <211> 27  
 <212> DNA  
 <213> artificial sequence  
  
 <220>

<223> forward PCR primer

<400> 36

gcactgcctc tgcaggtgtg tggcttc

27

<210> 37

<211> 27

<212> DNA

<213> artificial sequence

<220>

<223> forward PCR primer

<400> 37

aattcgcctc tgcaggtgtg tggcttc

27

<210> 38

<211> 26

<212> DNA

<213> artificial sequence

<220>

<223> reverse PCR primer

<400> 38

gccacacacc tgcagaggcg aattca

26

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**